The CytoTools AG reported that the treatment of the last patients in the phase II trial of DermaPro were completed at the end of June as planned. Now the process of data preparation and evaluation has begun and is being pursued intensively. This trial, carried out by the subsidiary DermaTools Biotech GmbH is aimed at establishing the dosages for the coming clinical phase III trial and the European approval of DermaPro. Up to the end of the treatment period, a total of 203 patients, at 15 centers in four countries, were treated with different active substance concentrations of DermaPro or a comparator product. Within the scope of the data preparation being carried out currently, the data bank entries of the clinical parameters of the most recently treated patients will be examined for consistency and plausibility. When this process is completed, the statistical evaluation is carried out so that the first results will be available at the beginning of August, from CW 32. These results form the basis for finalizing the design, and the submission of the application, for the coming European phase III trial for DermaPro in the diabetic foot indication. The application for approval of the subsequent phase III is currently in preparation, so that the submission can take place as soon as the results are available. Furthermore, the selection of suitable additional centers for phase III has begun, so that after the final approval for the trial has been granted, patient recruiting can quickly commence.